Sevelamer

DB00658ApprovedInvestigationalSmall moleculePhosphate BinderPhosphate-removing Agents

Sevelamer is a phosphate binder used to treat hyperphosphatemia. It is marketed by Genzyme under the trade name Renagel.

Chemical structure of Sevelamer
Mechanism
Curator reviewed
Primary indication
For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.Curator reviewed · 1 structured indication
Formula / weight
C6H12ClNO · 149.619 g/mol (avg)
First approval
Canada, 2000 · United States, 2006 · European Union, 2016
Code names
GT 16026 A · GT 335-012
Brand names
  • Renagel
  • Renvela

Resolves to

Compound
UNII941N5DUU5CCAS52757-95-6ChEMBLCHEMBL1201798PubChem3085017KEGGD01983
Clinical / RWD
RxNorm214824ATCV03AE02PharmGKBPA164781197
Structure
InChIKeyZNSIZMQNQCNRBW-UHFFFAOYSA-NSMILESNCC=C.ClCC1CO1

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
379Drug interactionsStructured to mechanism, not free text
Sign in
73Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
291Marketed productsAcross 11 countries and 98 labellers
Sign in
1ATC codeIncluding every combination product, plus 12 drug categories
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which other approved drugs treat the same conditions as Sevelamer, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In